儿童幼年特发性关节炎与色素绒毛结节性滑膜炎的鉴别诊断中滑液钙卫蛋白(S100A8/A9)含量检测的诊断价值 (单中心研究初步结果)
- 作者: Kozhevnikov A.N.1, Derkach E.A.1, Porohova A.A.1, Lukyanov S.A.1
-
隶属关系:
- H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery
- 期: 卷 13, 编号 1 (2025)
- 页面: 5-13
- 栏目: Clinical studies
- URL: https://journals.rcsi.science/turner/article/view/312529
- DOI: https://doi.org/10.17816/PTORS635368
- EDN: https://elibrary.ru/MPTCHZ
- ID: 312529
如何引用文章
详细
论证。幼年特发性关节炎是儿童最常见的慢性骨关节系统炎症性疾病,其中以寡关节型最常见。 色素绒毛结节性滑膜炎是一种少见的良性滑膜疾病,属于腱鞘巨细胞瘤类,可能表现为类似寡关节型幼年特发性关节炎的临床过程。幼年特发性关节炎与色素绒毛结节性滑膜炎的鉴别诊断常常存在困难。应用于幼年特发性关节炎的关节腔内激素可能对色素绒毛结节性滑膜炎产生不良影响。 为排除色素绒毛结节性滑膜炎而进行的骨科手术常对儿童带来较大负担。在疾病早期阶段,两种疾病在磁共振成像中的表现往往相似。部分研究显示,血清钙卫蛋白是幼年特发性关节炎的一个有前景的特异性生物标志物。
目的:研究寡关节型幼年特发性关节炎与色素绒毛结节性滑膜炎患者滑液中钙卫蛋白浓度。
材料与方法。采用酶联免疫吸附法检测42例寡关节型幼年特发性关节炎儿童和12例膝关节弥漫型色素绒毛结节性滑膜炎儿童滑液中的钙卫蛋白、白介素-6和肿瘤坏死因子α浓度。所有幼年特发性关节炎儿童在疾病首次发作时采集滑液,色素绒毛结节性滑膜炎儿童在治疗性诊断关节镜检查前采集滑液。
结果。研究发现,寡关节型幼年特发性关节炎儿童滑液中钙卫蛋白浓度显著多倍升高, 为108 [28.2;237] μg/mL,明显高于色素绒毛结节性滑膜炎儿童的1.53 [1.26;1.69] μg/mL (p<0.001)。在患有幼年特发性关节炎和色素绒毛结节性滑膜炎的患者滑液中,肿瘤坏死因子α和白介素-6 的浓度无统计学显著差异。ROC分析结果显示,滑液钙卫蛋白浓度高于2.9 μg/mL时提示幼年特发性关节炎(AUC 0.996±0.00479;95%可信区间0.926–1.000)。
结论。儿童寡关节型幼年特发性关节炎的诊断常因存在临床表现相似的非风湿性关节疾病而面临一定困难。滑液常规检测的主要炎症标志物在幼年特发性关节炎与色素绒毛结节性滑膜炎的鉴别诊断中无明显价值。滑液钙卫蛋白的定量指标可能成为指示幼年特发性关节炎的生物标志物之一。
关键词
作者简介
Aleksey N. Kozhevnikov
H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery
编辑信件的主要联系方式.
Email: Infant_doc@mail.ru
ORCID iD: 0000-0003-0509-6198
SPIN 代码: 1230-6803
MD, PhD, Cand. Sci. (Medicine)
俄罗斯联邦, Saint PetersburgElena A. Derkach
H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery
Email: serodedenko@gmail.com
ORCID iD: 0000-0002-9926-5281
MD
俄罗斯联邦, Saint PetersburgAleksandra A. Porohova
H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery
Email: sasha.porokhova@yandex.ru
ORCID iD: 0009-0008-9820-6563
MD
俄罗斯联邦, Saint PetersburgSergey A. Lukyanov
H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery
Email: sergey.lukyanov95@yandex.ru
ORCID iD: 0000-0002-8278-7032
SPIN 代码: 3684-5167
MD, PhD, Cand. Sci. (Medicine)
俄罗斯联邦, Saint Petersburg参考
- Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. EDN: MKWHUD doi: 10.1016/S0140-6736(07)60363-8
- Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13. EDN: SOKSUT doi: 10.1186/1546-0096-12-13
- Giancane G, Consolaro A, Lanni S, et al. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187–207. EDN: YGSPXE doi: 10.1007/s40744-016-0040-4
- Kim KH, Kim DS. Juvenile idiopathic arthritis: diagnosis and differential diagnosis. Korean J Pediatr. 2010;53(11):931–935. doi: 10.3345/kjp.2010.53.11.931
- Tsurikova NA, Ligostaeva EA, Zholobova ES. Oligoarticular juvenile idiopathic arthritis at early stages of disease: a way to verification of diagnosis. Clinical Practice in Pediatrics. 2017;12(2):33–38. EDN: YNUAHF doi: 10.20953/1817-7646-2017-2-33-38
- Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734. EDN: UKDZNY doi: 10.1002/acr.23870
- Kozhevnikov AN, Pozdeeva NA, Konev MA, et al. Juvenile arthritis: clinical manifestations and differential diagnosis and differential diagnosis. Pediatric Traumatology, Orthopaedics and Reconstructive Surgery. 2014;4(2):66–73. EDN: TGIWBD doi: 10.17816/PTORS2466-73
- Fecek C, Carter KR. Pigmented villonodular synovitis. In: StatPearls. StatPearls Publishing; 2023.
- Turkucar S, Makay B, Tatari H, et al. Pigmented villonodular synovitis: four pediatric cases and brief review of literature. J Postgrad Med. 2019;65(4):233–236. doi: 10.4103/jpgm.JPGM_305_19
- Karami M, Soleimani M, Shiari R. Pigmented villonodular synovitis in pediatric population: review of literature and a case report. Pediatr Rheumatol Online J. 2018;16(1):6. EDN: HZMVEO doi: 10.1186/s12969-018-0222-4
- Şahin E, Tatari H. Pigmented villonodular synovitis of the knee confused with juvenile rheumatoid arthritis in a 3-year-old child: a case report. J Surg Med. 2020;4(9):838–841. doi: 10.28982/josam.716164
- Kittanakom S, Shajib MS, Garvie K, et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:1450970. doi: 10.1155/2017/1450970
- Wang S, Song R, Wang Z, et al. S100A8/A9 in inflammation. Front Immunol. 2018;9:1298. doi: 10.3389/fimmu.2018.01298
- Inciarte-Mundo J, Frade-Sosa B, Sanmartí R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022;13:1001025. EDN: CXOGZE doi: 10.3389/fimmu.2022.1001025
- Pathirana WGW, Chubb SP, Gillett MJ, et al. Faecal calprotectin. Clin Biochem Rev. 2018;39(3):77–90.
- Avdeeva AS. Clinical significance of calprotectin in rheumatic diseases. Rheumatology Science and Practice. 2018;56(4):494–499. EDN: XYBWFV doi: 10.14412/1995-4484-2018-494-499
- Carrión M, Juarranz Y, Martínez C, et al. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2013;52(12):2177–2186. doi: 10.1093/rheumatology/ket315
- Romano M, Gerloni V, De Lucia O, et al. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2021;39(5):1132–1140. EDN: OHJSIP doi: 10.55563/clinexprheumatol/5tckci
- d’Angelo DM, Attanasi M, Di Donato G, et al. The role of serum calprotectin in defining disease outcomes in non-systemic juvenile idiopathic arthritis: a pilot study. Int J Mol Sci. 2023;24(2):1671. EDN: CMXPYF doi: 10.3390/ijms24021671
- Denisov LN, Nesterenko VA, Smirnov AV. Pigmented villonodular synovitis: literature review and case report. Modern Rheumatology Journal. 2022;16(3):91–95. EDN: LNWUMR doi: 10.14412/1996-7012-2022-3-91-95
- Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40(6):539–546. doi: 10.1016/j.semarthrit.2010.07.005
- Baroni E, Russo BD, Masquijo JJ, et al. Pigmented villonodular synovitis of the knee in skeletally immature patients. J Child Orthop. 2010;4(2):123–127. doi: 10.1007/s11832-009-0236-z
- Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol. 2016;17(2):10. EDN: NHDZJE doi: 10.1007/s11864-015-0385-x
- Alexeeva E.I. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current Pediatrics. 2015;14(1):78–94. EDN: TIHOVF doi: 10.15690/vsp.v14i1.1266
- Mahmud SA, Binstadt BA. Autoantibodies in the pathogenesis, diagnosis, and prognosis of juvenile idiopathic arthritis. Front Immunol. 2019;9:3168. doi: 10.3389/fimmu.2018.03168
- Romand X, Bernardy C, Nguyen MVC, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691–698. doi: 10.1016/j.jbspin.2019.01.003
- Jeong SJ. The role of fecal calprotectin in pediatric disease. Korean J Pediatr. 2019;62(8):287–291. doi: 10.3345/kjp.2019.00059
- Marushko T, Holubovska Y, Kulchytska YE. Evaluation of serum calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis. Journal of Pediatric and Neonatal Individualized Medicine. 2021;10(1):e100140. doi: 10.7363/100140
- Altobelli E, Angeletti PM, Petrocelli R, et al. Serum calprotectin a potential biomarker in juvenile idiopathic arthritis: a meta-analysis. J Clin Med. 2021;10(21):4861. EDN: GYXALT doi: 10.3390/jcm10214861
- Boyko Y, Ivanova V, Vakaruk M, et al. Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment. Reumatologia. 2020;58(4):202–207. EDN: JTXAVJ doi: 10.5114/reum.2020.98431
- Salari P, Grassi M, Cinti B, et al. Synovial fluid calprotectin for the preoperative diagnosis of chronic periprosthetic joint infection. J Arthroplasty. 2020;35(2):534–537. EDN: DDBCRI doi: 10.1016/j.arth.2019.08.052
- Boffa A, Merli G, Andriolo L, et al. Synovial fluid biomarkers in knee osteoarthritis: a systematic review and quantitative evaluation using BIPEDs criteria. Cartilage. 2021;13(Suppl 1):82S–103S. EDN: QPLRZJ doi: 10.1177/1947603520942941
- Kostik MM, Chikova IA, Isupova EA, et al. The use of tocilizumab in 40 patients with polyarticular juvenile idiopathic arthritis: the results of a retrospective study. Current Pediatrics. 2017;16(2):148–155. EDN: YRGVSX doi: 10.15690/vsp.v16i2.1716
- Tsujioka Y, Nishimura G, Sugimoto H, et al. Imaging findings of juvenile idiopathic arthritis and autoinflammatory diseases in children. Jpn J Radiol. 2023;41(11):1186–1207. EDN: AZVCVW doi: 10.1007/s11604-023-01447-6
- Chen C, Zheng L, Zeng G, et al. Identification of potential diagnostic biomarkers for tenosynovial giant cell tumour by integrating microarray and single-cell RNA sequencing data. J Orthop Surg Res. 2023;18(1):905. EDN: EROOHX doi: 10.1186/s13018-023-04279-2
- Liu Y, Liang X, Xu B, et al. Identification of potential biomarkers of pigmented villonodular synovitis by transcriptome analysis. Research Square. 2022. doi: 10.21203/rs.3.rs-1707206/v1
- Heng H, Li D, Su W, et al. Exploration of comorbidity mechanisms and potential therapeutic targets of rheumatoid arthritis and pigmented villonodular synovitis using machine learning and bioinformatics analysis. Front Genet. 2023;13:1095058. EDN: GVONHD doi: 10.3389/fgene.2022.1095058
- O’Keefe RJ, Rosier RN, Teot LA, et al. Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J. 1998;18:26–34.
- Kozhevnikov AN, Pozdeeva NA, Derkach EA, et al. A pilot study of serum calprotectin ability to be a potential biomarker of erosive course juvenile arthritis. African Journal of Rheumatology. 2023;11(2):110–115.
补充文件
